Invesco Ltd. Has $11.16 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Invesco Ltd. is a global investment management firm that manages over $1 trillion in assets under management (AUM). One of its holdings is Amicus Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing treatments for rare genetic disorders.

Amicus Therapeutics, Inc. has a market capitalization of approximately $2.5 billion and is listed on the NASDAQ stock exchange under the ticker symbol "FOLD". The company's pipeline includes several potential treatments for rare genetic disorders, including its lead product, Gaucher disease enzyme replacement therapy (ERT), which is approved in the United States, Europe, and other countries.

Invesco Ltd.'s $11.16 million holding in Amicus Therapeutics, Inc. represents a small portion of the company's overall AUM. However, it reflects Invesco's confidence in the potential of Amicus Therapeutics' pipeline and its ability to generate revenue from its approved products and future product candidates.

It is important to note that this information is based on publicly available data and may be subject to change. It is always recommended to consult with a financial advisor before making any investment decisions.